CRL
Charles River Laboratories International, Inc.195.22
-2.93-1.48%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
9.61BP/E (TTM)
-Basic EPS (TTM)
-1.52Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
CFO transition announced
Charles River Laboratories announced on September 12, 2025, that CFO Flavia H. Pease will resign effective September 29, 2025, to pursue another opportunity, with no disagreements on company matters. Michael G. Knell, the 49-year-old Chief Accounting Officer since 2017, steps in as interim CFO until a permanent hire. The board launched a search for a successor. No disruption expected. The company reaffirms its 2025 revenue and non-GAAP EPS guidance amid a challenging demand environment.
8-K
Q2 revenue edges up, probe closed
Charles River Laboratories reported Q2 2025 revenue of $1.03 billion, up 0.6% from last year but down 0.5% organically, with DSA segment revenue falling 2.4% on lower volumes yet non-GAAP EPS climbing 11.4% to $3.12 on margin gains and restructuring savings. The company closed its U.S. DOJ probe into non-human primate shipments, easing a key overhang. Guidance now sees organic revenue down 3.0% to 1.0% for 2025, with non-GAAP EPS at $9.90–$10.30. Restructuring costs persist.
IPO
Website
Employees
Sector
Industry
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
ICLR
ICON plc
182.45-1.92
IDXX
IDEXX Laboratories, Inc.
693.18-6.95
IQV
IQVIA Holdings, Inc.
221.68-1.95
LH
Labcorp Holdings Inc.
258.11-5.22
NOTV
Inotiv, Inc.
0.68-0.02
RVTY
Revvity, Inc.
96.27-2.81
TMO
Thermo Fisher Scientific Inc
570.16-5.75
WAT
Waters Corporation
378.53-6.89